Curtis Cooper profile picture

Contact Information

Curtis Cooper, MD, FRCPC
613-737-8899 ext72296
ccooper@ottawahospital.on.ca

Research Activities

2014
A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Samatasvir and IDX21437 Given in Combination with or without Ribavirin in Subjects with Chronic Hepatitis C Infection

 A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults

A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects with Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)

2013
 A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B

Preventing the Progression of Liver Fibrosis with Metformin in HCV-HIV Co-infected and HCV Mono-infected Patients with Insulin Resistance

Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment naïve genotypes 1, 2, 3 or 4 in subjects co-infected

 A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis

Study Investigating the Management of G1 Chronic Hepatitis C Patients Treated with VICTRELISTM +Peg-Riba:A Real-LifE Observational Trial in Canada (S.I.M.P.L.E)]

A randomized prospective open label study of switching to raltegravir based ART compared to maintaining ritonavir boosted PI-based ART on liver fibrosis progression in HIV-HCV co-infected patients. (Raltegravir Switch Study)